These results are consistent with the reported anti‐fibrotic effects of VASH‐1 in the experimental pulmonary fibrosis (Wang et al. 2010) and diabetic nephropathy models (Nasu et al. 2009; Saito et al. 2011). This evidence concerns the gene VASH1 and pulmonary fibrosis.